The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.

@article{Stover2005TheSM,
  title={The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.},
  author={Elizabeth H Stover and Jing Chen and Benjamin Hoyoung Lee and Jan Cools and Elizabeth P. McDowell and Jennifer Adelsperger and Dana Cullen and Allison Coburn and Sandra A. Moore and Rachel O. Okabe and Doriano Fabbro and Paul William Manley and James D Griffin and Dwight Gary Gilliland},
  journal={Blood},
  year={2005},
  volume={106 9},
  pages={3206-13}
}
AMN107 is a small molecule tyrosine kinase inhibitor developed, in the first instance, as a potent inhibitor of breakpoint cluster region-abelson (BCR-ABL). We tested its effectiveness against fusion tyrosine kinases TEL-platelet-derived growth factor receptorbeta (TEL-PDGFRbeta) and FIP1-like-1 (FIP1L1)-PDGFRalpha, which cause chronic myelomonocytic leukemia and hypereosinophilic syndrome, respectively. In vitro, AMN107 inhibited proliferation of Ba/F3 cells transformed by both TEL-PDGFRbeta… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

Similar Papers

Loading similar papers…